Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology

08-01-2024 | SCLC | case report

Transformation of epidermal growth factor receptor-mutated non-small cell lung cancer into small cell lung cancer—case report

Authors: Nino Rafael Müser, Klaus Kirchbacher, Georg-Christian Funk

Published in: memo - Magazine of European Medical Oncology

Login to get access

Summary

Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) generally has a favorable prognosis when compared to lung cancer without this alteration due to the advent of EGFR tyrosine kinase inhibitors (TKI). However, during treatment with these drugs, acquired resistance and in turn progressive disease eventually occur. One such resistance mechanism is the transformation of EGFR-mutant adenocarcinoma into small cell lung cancer (SCLC) which has been described in a small subset of patients. We report the case of a woman with stage IV adenocarcinoma progressing and transforming into SCLC while being treated with Afatinib at our institution. This case also highlights the importance of rebiopsy in progressive patients receiving TKI for EGFR-mutated NSCLC.
Literature
1.
Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725–37. Oct.CrossRefPubMedPubMedCentral
2.
Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Sci Transl Med. 2011 Mar 23;3(75):75ra26.
3.
Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):e165–72. Apr.CrossRefPubMedPubMedCentral
4.
Piper-Vallillo AJ, Sequist LV, Piotrowska Z. Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. J Clin Oncol. 2020;38(25):2926–36. Sep.CrossRef
5.
Mambetsariev I, Arvanitis L, Fricke J, Pharaon R, Baroz AR, Afkhami M, et al. Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. J Clin Med. 2022;5;11(5):1429. Mar.CrossRefPubMed
6.
Zakowski MF, Ladanyi M, Kris MG. EGFR Mutations in Small-Cell Lung Cancers in Patients Who Have Never Smoked. N Engl J Med. 2006;13;355(2):213–5. Jul.CrossRef
7.
Ferrer L, Giaj Levra M, Brevet M, Antoine M, Mazieres J, Rossi G, et al. A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2019 Jan;14(1):130–4.
8.
Marcoux N, Gettinger SN, O’Kane G, Arbour KC, Neal JW, Husain H, et al. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019;1;37(4):278–85. Feb.CrossRefPubMed
9.
Roca E, Gurizzan C, Amoroso V, Vermi W, Ferrari V, Berruti A. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis. Cancer Treat Rev. 2017;1;59:117–22. Sep.CrossRefPubMed
10.
Zhang CY, Sun H, Su JW, Chen YQ, Zhang SL, Zheng MY, et al. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival. Lung Cancer. 2023;1;175:68–78. Jan.CrossRefPubMed
11.
Minari R, Bordi P, Del Re M, Facchinetti F, Mazzoni F, Barbieri F, et al. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy. Lung Cancer Amst Neth. Jan, Vol. 115. 2018. pp. 21–7.
12.
Lee JK, Lee J, Kim S, Kim S, Youk J, Park S, et al. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. J Clin Oncol Off J Am Soc Clin Oncol. 2017 Sep 10;35(26):3065–74.
13.
Wang W, Xu C, Chen H, Jia J, Wang L, Feng H, et al. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study. Lung Cancer Amst Neth. May, Vol. 155. 2021. pp. 20–7.
14.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;6;379(23):2220–9. Dec.CrossRef
Metadata
Title
Transformation of epidermal growth factor receptor-mutated non-small cell lung cancer into small cell lung cancer—case report
Authors
Nino Rafael Müser
Klaus Kirchbacher
Georg-Christian Funk
Publication date
08-01-2024
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00953-7
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits